Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer

Alice Bergamini, Simone Ferrero, Umberto Leone Roberti Maggiore, C. Scala, Francesca Pella, Valerio Gaetano Vellone, Micaela Petrone, Emanuela Rabaiotti, R. Cioffi, Massimo Candiani, Giorgia Mangili

Research output: Contribution to journalReview article

Abstract

Introduction: The prognosis of patients affected by ovarian cancer has not substantially changed in the last decades and improving survival still remains a challenge. In the promising era of ‘personalized therapy’ several new biologic therapies are currently being investigated: in this setting, targeting the folate receptor (FR) has been considered a new potential strategy for biologic therapy. Areas covered: The aim of the current review is to summarize, giving a critical overview,promising folate receptor alpha antagonists under preclinical or early clinical development for ovarian cancer. Expert opinion: Two categories of therapeutics are included in this class: FRα targeted mAbs and FRα-binding-ADC (Antibody drug conjugates); both share the interesting possibility of selecting patients via a biomarker which is already available. In the first class, farletuzumab has reached the most advanced stage in clinical evaluation and results of a Phase II randomized trial are awaited to assess its efficacy in a specific patients’ setting. MOv18 IgE represents a novel strategy to target FRα expressing cells, which has shown encouraging results in preclinical studies: further evaluation is needed in the clinical setting. IMGN 853 is an innovative FRα-binding ADC under development, with only preliminary results of a Phase I trial available.

Original languageEnglish
Pages (from-to)1405-1412
Number of pages8
JournalExpert Opinion on Investigational Drugs
Volume25
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Keywords

  • Farletuzumab
  • folate receptor
  • folate-conjugates
  • ovarian cancer
  • target therapies

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer'. Together they form a unique fingerprint.

  • Cite this